Jazz Pharmaceuticals plc
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $4.3B | $4.1B | $3.8B | $3.7B | $3.1B |
| Operating income | -$430.2M | $716.6M | $578.6M | -$65.5M | $170.3M |
| Cash from operations | $1.4B | $1.4B | $1.1B | $1.3B | $778.5M |
| Capital expenditure | $58.8M | $38.1M | $24.0M | $29.0M | $27.6M |
| Free cash flow | $1.3B | $1.4B | $1.1B | $1.2B | $750.9M |
| Share repurchases | $125.0M | $311.4M | $269.8M | $54,000 | $0 |
| Impairments | $0 | $0 | $0 | $133.6M | $0 |
| Total assets | $11.7B | $12.0B | $11.4B | $10.8B | $12.3B |
| Total debt | $5.4B | $6.2B | $5.8B | $5.8B | $6.4B |
Shares outstanding 62.7M · Free float 57.2%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.